Argenx vs Biontech
Argenx is the larger business, with $4.15bn of revenue in fiscal 2025 against $3.24bn for Biontech (1.3 times as much). Argenx grew faster (89.9% against 9.0%). Argenx kept more of each dollar of sales as profit: a net margin of 31.1% against -39.6%. Argenx carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | ArgenxARGX, 2025 | BiontechBNTX, 2025 |
|---|---|---|
| Revenue | $4.15bn | $3.24bn |
| Revenue growth | 89.9% | 9.0% |
| Net income | $1.29bn | −$1.28bn |
| Operating margin | 25.4% | -49.0% |
| Net margin | 31.1% | -39.6% |
| Return on equity | 20.2% | -6.0% |
| Free cash flow | $679m | $318m |
| Cash | $3.49bn | $9.01bn |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | 0.0% |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $55.65bn | $21.84bn |
| Price vs our value range | — | Below our value range |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 27 sales |